Clinical trial
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
NCT02392208 is registered in ClinicalTrials.gov with University of Michigan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
- Lead sponsor
- University of Michigan
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 31, 2015
- Completion date
- March 31, 2016
- Enrollment
- 8 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
end-stage renal disease, stage 5 chronic kidney disease